{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:48:50Z","timestamp":1767016130731,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jpba.2021.114416","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T23:18:24Z","timestamp":1633735104000},"page":"114416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Identification of Novel Impurity of Ziprasidone"],"prefix":"10.1016","volume":"207","author":[{"given":"Sunil R.","family":"Murkute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girij P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.G.","family":"Vasantharaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-472X","authenticated-orcid":false,"given":"Krishnamurthy","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu M.","family":"Godbole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritesh R.","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114416_bib1","first-page":"191","article-title":"A rapid stability-indicating LC method for ziprasidone hydrochloride","volume":"65","author":"Singh","year":"2007","journal-title":"Chromatographia"},{"key":"10.1016\/j.jpba.2021.114416_bib2","first-page":"2703","article-title":"Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone","volume":"100","author":"Hong","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.114416_bib3","first-page":"713","article-title":"Development and validation of an HPLC method for determination of ziprasidone and its impurities in pharmaceutical dosage forms","volume":"94","author":"Pavlovic","year":"2011","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.jpba.2021.114416_bib4","first-page":"286","article-title":"Development and validation of stability indicating UPLC assay method for ziprasidone active pharma ingredient","volume":"3","author":"Mittal","year":"2012","journal-title":"Chron. Young-.-. Sci."},{"key":"10.1016\/j.jpba.2021.114416_bib5","first-page":"809","article-title":"Development of rapid and robust stability-indicating method for analysis of ziprasidone (hydrochloride and freebase) as drug substance and in medicines by UPLC","volume":"69","author":"Zakowiecki","year":"2012","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.jpba.2021.114416_bib6","first-page":"879","article-title":"Characterization of a novel metabolite intermediate of Ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS\/MS, hydrogen\/deuterium exchange, and chemical derivatization","volume":"33","author":"Zhuang","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2021.114416_bib7","first-page":"755","article-title":"The importance and the challenges of impurity profiling in modern pharmaceutical analysis","volume":"25","author":"Gorog","year":"2006","journal-title":"TrAC Trends Ana. Chem."},{"key":"10.1016\/j.jpba.2021.114416_bib8","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Q3A(R2) Impurities in New Drug Substances (2006) 1\u201315."},{"volume":"Volume 4","first-page":"1","year":"2000","key":"10.1016\/j.jpba.2021.114416_bib9"},{"first-page":"4245","year":"2019","series-title":"European Pharmacopeia (Ph. Eur.)","key":"10.1016\/j.jpba.2021.114416_bib10"},{"key":"10.1016\/j.jpba.2021.114416_bib11","unstructured":"R.B. Frank, W.G. Adam, R.H. Harry, R.L. Jr.Kyle, European Patent Office, EP1476162B1, 2007."},{"key":"10.1016\/j.jpba.2021.114416_bib12","first-page":"1559","article-title":"On the photoisomerization of the benzisothiazole portion of ziprasidone","volume":"44","author":"Thomas","year":"2003","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.jpba.2021.114416_bib13","unstructured":"V. Sundaram, V.B.R. Uppala, M. Venkateswarlu, C. Vijayawardhan, US 7777037B2, 2010."},{"key":"10.1016\/j.jpba.2021.114416_bib14","unstructured":"United States Pharmacopeia, USP43-NF38\u20134699 \u3008https:\/\/online.uspnf.com\/uspnf\/document\/1_GUID-E5A07C93\u201343F8\u20134B1C-BDFB-6295F6B5B4B5_9_en-US\u3009."},{"issue":"6","key":"10.1016\/j.jpba.2021.114416_bib15","first-page":"739","article-title":"Assessment and quantification of genotoxic impurities of Ziprasidone an antipsychotic drug","volume":"Vol 7","author":"Katta","year":"2015","journal-title":"J. Chem. Pharm. Res."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521005276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521005276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:18:47Z","timestamp":1760001527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521005276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":15,"alternative-id":["S0731708521005276"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114416","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Novel Impurity of Ziprasidone","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114416"}}